Search

Displaying results 2771 - 2780 of 4859 in total
  1. Drug

    Lasmiditan

    go.drugbank.com/drugs/DB11732
    ApprovedInvestigational

    [L9338,L9356] It was also approved by the European Commission on August 17, 2022.[L43997] Traditionally, the triptan class of anti-migraine medications (e.g.

  2. Drug

    Muraglitazar

    go.drugbank.com/drugs/DB06510
    Investigational

    It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes.

  3. Drug

    Trolamine salicylate

    go.drugbank.com/drugs/DB11079
    Approved

    It also displays low systemic absorption upon dermal or topical administration [A32190] and has low skin irritant properties [A32191]. … It is a topical analgesic used for temporary relief of minor pain associated with arthritis, simple backache, muscle strains, sprains, and bruises.

  4. Drug

    Retifanlimab

    go.drugbank.com/drugs/DB15766
    ApprovedInvestigational

    Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). By bloc...

  5. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    Cosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1). On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous c...

  6. Drug

    Adenosine phosphate

    go.drugbank.com/drugs/DB00131
    ApprovedInvestigationalNutraceuticalWithdrawn

    Adenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937]

  7. Drug

    Lumiracoxib

    go.drugbank.com/drugs/DB01283
    ApprovedWithdrawn

    On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver

  8. Drug

    Mephentermine

    go.drugbank.com/drugs/DB01365
    ApprovedWithdrawn

    It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia.

  9. Drug

    Everolimus

    go.drugbank.com/drugs/DB01590
    ApprovedInvestigational

    It is currently used as an immunosuppressant to prevent rejection of organ transplants.

  10. Drug

    Dexbrompheniramine

    go.drugbank.com/drugs/DB00405
    Approved

    Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.